Stock Ratings / Health Care / ELVN / dividends

BHC (69) VKTX (44) TLX (54) DYN (40) ⌘ Pro Terminal →

Enliven Therapeutics Inc. (ELVN) Dividend Safety Gauge & 10-Year DRIP Compounder

$45.08 +0.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $45.05

Enliven Therapeutics Inc. (ELVN) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.30B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $45.05 (-0.07%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELVN)Realized 20D OHLCV Swing Band: ±9.6%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY ELVN SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (28% of score)

FRED Regime × Technicals: 64% of 52W Range • RSI-14 at 51 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$40.98-8.9% Next Q

Q2 (-2Q)

Grade E$37.32+11.3% Next Q

Q3 (-1Q)

Grade E$41.52+8.6% Next Q

Current

Grade D-$45.08-7.4% Hist 90D α

Trajectory: E (32) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELVN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELVN currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($48.70) and Max Pain ($47.33) forces dealer call-delta covering toward $65.44.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ELVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELVN)

✓Walkthrough of ELVN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ELVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.34%▲ ASCENDING CHANNEL

2026-10-30O $44.92H $45.87L $44.09C $45.08VOL 1.24M

RES: $73.16SUP: $37.35SMA50: $48.70SMA200: $42.73

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELVN Butterfly Map → + Track ELVN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ELVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ELVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELVN)

Health Care Rank #629 of 1016 ⚔️ BHC vs ELVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELVN vs. BHC, VKTX, TLX, DYN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Enliven Therapeutics Inc. (ELVN) ranks #629 by composite RQD confidence (40/100, grade D-) and #200 by equity capitalization ($3.30B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with ELVN at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ELVN ACTIVE Enliven Therapeutics Inc.	D-	40/100	—	—	-26.2%	+0.67%	$3.30B	Benchmark Subject
BHC Bausch Health Companies Inc.	C+	69/100	21.2x	—	7.6%	+28.76%	$3.33B	/bhc-vs-elvn →
VKTX Viking Therapeutics Inc.	D	44/100	—	—	-35.0%	+5.92%	$3.38B	/vktx-vs-elvn →
TLX Telix Pharmaceuticals Limited	D+	54/100	—	—	—	+2.70%	$3.22B	/tlx-vs-elvn →
DYN Dyne Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.35%	$3.18B	/dyn-vs-elvn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001672619

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enliven Therapeutics Inc. (ELVN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$103.7M, operating cash flow of -$70.3M, and free cash flow of -$70.3M (+3.9% YoY). On the balance sheet, ELVN closed FY2025 with $476.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$103.7M	-$70.3M	-$70.3M	$476.2M	—
FY2024 (FY)	2024-12-31	$0	-$89.0M	-$73.2M	-$73.2M	$325.8M	—
FY2023 (FY)	2023-12-31	$0	-$71.6M	-$61.3M	-$61.3M	—	—

3. ELVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Enliven Therapeutics Inc. (NASDAQ: ELVN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $45.08 (+0.67% 1D, market cap $3.30B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELVN ranks #629 in composite RQD confidence.

How does ELVN compare to BHC and VKTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELVN carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -26.2%. By comparison, BHC (Bausch Health Companies Inc.) holds a C+ grade (69/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.33B) and VKTX (Viking Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ELVN?

Per ELVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672619), Enliven Therapeutics Inc. generated $0 in revenue, -$103.7M in net income, and -$70.3M in free cash flow against $476.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ELVN trading relative to its 50-day, 200-day, and 52-week technical levels?

ELVN last traded at $45.08 (+0.67% on volume of 909,486 shares), positioning the stock -7.43% below its 50-day simple moving average ($48.70) and +5.50% above its 200-day simple moving average ($42.73). Across its 52-week range of $14.79 to $62.32, ELVN sits at the 63.7% percentile with a 14-day RSI of 51.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($40.75 to $49.41).

ELVN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ELVN pay a dividend and is it safe?

Enliven Therapeutics Inc. (ELVN) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ELVN RQD Cockpit ELVN 12M Forecast ELVN Earnings & Move ELVN Dividends & DRIP ELVN Insiders & 13F ELVN Whale Options ELVN Profit Sankey ELVN News & Why